Amarin(AMRN.US)

Event Tracking

Nov9

Amarin Publishes New Analysis Proving VASCEPA/VAZKEPA Reduces Cardiovascular Risk

21:16

Oct29

Amarin released FY2025 Q3 earnings on October 29 Pre-Market EST, actual revenue USD 49.67 M (forecast USD 43.1 M), actual EPS USD -0.4 (forecast USD -0.4298)

13:30

Amarin released FY2025 9 Months Earnings on October 29 Pre-Market EST, with actual revenue of USD 164.43 M and actual EPS of USD -1.8822

13:30

Oct27

Amarin Supports FDA Revision to Non-Statins Fibrate Drug Label

13:29

Oct22

Amarin to Release FY2025 Q3 Earnings on October 29 Pre-Market EST, Forecast Revenue USD 34.65M, EPS USD -0.4298

00:30

Aug31

Amarin Reveals Anti-Inflammatory Mechanism of EPA

12:30

Schedules & Filings

Schedules

Filings

Oct29

Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 49.67 M, Net Income -7.738 M, EPS -0.4

Jul30

Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 72.74 M, Net Income -14.14 M, EPS -0.6822

May7

Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 42.02 M, Net Income -15.7 M, EPS -0.8

Stock List

Top Gainers

Top Decliners

China Concepts

Symbol

Price

%Chg

Change